- Vortioxetine: A Unique Antidepressant for Major Depressive Disorder
Vortioxetine received FDA approval for the treatment of major depressive disorder in 2013 The drug is an SSRI, but it also acts as a 5HT agonist, antagonist, and transport inhibitor 3
- Levomilnacipran, Vilazodone, and Vortioxetine Provide Similar Benefits . . .
Among patients treated for major depressive disorder (MDD), levomilnacipran, vilazodone, and vortioxetine are not associated with significantly greater benefits or harms compared with standard
- Pretreatment Functioning Associated With Anxiolytic Efficacy of . . .
In the second clinical trial (Clinicaltrials gov identifier: NCT00788034), 687 participants received vortioxetine 5 mg or 10 mg for 20 weeks At the end of the 20-week period, responders were
- Treating MDD in Older Patients: Adverse Effects of Drug Therapy . . .
A recent systematic review and meta-analysis assessed the adverse effects of antidepressant therapies among older patients (≥65 years old) with major depressive disorder () Study authors
- PATIENT FACT SHEET
nefazodone (Serzone®), trazodone (Desyrel®), vilazodone (Viibryd®), and vortioxetine (Trintellix®) The most common side effects of mixed 5-HT agents include sedation,
- Antidepressants and Weight Gain
Mixed Serotonergic Effects (Mixed 5-HT): examples of mixed 5-HT agents include nefazodone (Serzone®), trazodone (Desyrel®), vilazodone , and vortioxetine (Trintellix®) The most common side
- UCSD Performance-Based Skills Assessment: A Valid Measure of . . .
Participants were randomly assigned to an 8-week course of vortioxetine 10 20 mg, placebo, or a drug such as escitalopram 10 20 mg or paroxetine 20 mg for similar indications Construct validity
|